Zealand Pharma A/S Interim report for Q (un-audited)
|
|
- Reginald Jonah McCarthy
- 5 years ago
- Views:
Transcription
1 Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and securities of DKK 526 (EUR 71) million on 31 March 2012 Financial guidance for 2012 maintained Copenhagen, 25 April 2012 Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of peptide drugs, reports pipeline progress, a net profit and an increase in cash and securities for the interim period 1 January to 31 March Highlights for Q Revenue of DKK (EUR 16.2) million consisting of milestone payments from Sanofi and Helsinn Healthcare (Q1 2011: DKK 0.0 (EUR 0.0) million). Royalty expenses of DKK 15.3 (EUR 2.1) million (Q1 2011: DKK 0.0 (EUR 0.0) million). Net operating expenses of DKK 39.4 (EUR 5.3) million (Q1 2011: DKK 43.3 (EUR 5.8) million), which is in line with expectations. A net profit of DKK 65.7 (EUR 8.8) million (Q1 2011: A net loss of DKK 44.9 (EUR 6.0) million). Cash and securities on 31 March 2012 amounted to DKK (EUR 70.7) million (31 March 2011: DKK (EUR 52.4) million). Pipeline advances: Lixisenatide (Lyxumia ) for Type 2 diabetes - In registration phase in Europe (partnership with Sanofi): - Positive top-line results from GetGoal-P, supportive for this once-daily GLP-1 drug candidate - The GetGoal-P results marked the completion of the global GetGoal Phase III program for lixisenatide and triggered a USD 20 million milestone payment to Zealand Pharma from Sanofi Elsiglutide for the prevention of chemotherapy-induced diarrhea (partnership with Helsinn Healthcare): - Initiation of a Phase IIa study to evaluate the efficacy and safety of elsiglutide in patients with colorectal cancer, treated with chemotherapy Zealand Pharma A/S Page 1 of 11
2 David Solomon, CEO and President of Zealand Pharma commented on the report: During the first months of 2012, we have further strengthened our cash position alongside important progress for our pipeline of peptide drug candidates. Our partner, Sanofi, completed the global Phase III program, GetGoal, for lixisenatide (Lyxumia ) now in the registration phase in Europe with positive results from the GetGoal-P study supporting the intended use of this novel once-daily GLP-1 in the treatment of patients Type 2 diabetes. We look forward to a response from the European Authorities on lixisenatide and to Sanofi s planned filing in the US later this year while we concentrate on advancing the development of our internal peptide drug programs. Financial outlook for 2012 Zealand Pharma maintains its financial expectations for 2012 as announced in the 2011 full year results announcement on 15 March 2012 (Company Announcement 07/2012). Revenue from milestone payments received in Q from Sanofi and Helsinn Healthcare amounts to DKK 120 (EUR 16) with related royalty expenses of DKK 15 (EUR 2) million. The timing of other potential milestone based payments from partners is largely outside the control of Zealand Pharma, and therefore no further revenue guidance is provided for the full year at this point. Total net operating expenses are expected in the range of DKK (EUR 20-23) million. # # # For further information, please contact: David H. Solomon, President and Chief Executive Officer Tel: Hanne Leth Hillman, Vice President for IR & Corporate Communication Tel: , hlh@zealandpharma.com About Zealand Pharma Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biotechnology company based in Copenhagen, Denmark with a mature clinical pipeline of innovative peptide drugs. The company's lead invention is lixisenatide (Lyxumia 1) ), a oncedaily GLP-1 agonist licensed to Sanofi for the treatment of Type 2 diabetes. In October, Sanofi submitted a marketing authorization application (MAA) for lixisenatide in Europe and submission for regulatory approval in the United States is expected in Q Zealand Pharma also has a collaboration with Boehringer Ingelheim covering dual acting glucagon/glp-1 agonists, including ZP2929, for the treatment of diabetes and obesity, and a license agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the prevention of chemotherapy-induced diarrhea. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs, and all drug candidates in its pipeline have been identified through the company's own drug discovery activities. Zealand Pharma's products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: Note 1) Lyxumia is the intended trademark for lixisenatide. Lixisenatide is not currently approved or licensed anywhere in the world. Zealand Pharma A/S Page 2 of 11
3 Business highlights in Q Lixisenatide (Lyxumia ) for Type 2 diabetes (in partnership with Sanofi) o In February, Zealand Pharma and Sanofi announced positive top-line results from the GetGoal-P study, one of the studies in the global GetGoal Phase III program, assessing the efficacy and safety of lixisenatide in Type 2 diabetes. Results from GetGoal-P, which involved 484 patients with Type 2 diabetes, showed that lixisenatide achieved its primary efficacy endpoint of significantly reducing blood glucose levels (HbA1c) compared to placebo (p<0.0001) as an add-on therapy to pioglitazone with or without metformin. Safety and tolerability results were consistent with other studies within the GetGoal program. o The positive top-line results from the GetGoal-P study marked the completion of the global GetGoal Phase III program for lixisenatide, which has involved more than 4,500 patients with Type 2 diabetes. The completion of the GetGoal Phase III program triggered a milestone payment of USD 20 million to Zealand Pharma from Sanofi. Elsiglutide for the prevention of chemotherapy-induced diarrhea (in partnership with Helsinn Healthcare) o In March, Helsinn Healthcare advanced the development of elsiglutide, dosing the first patients in a Phase IIa study to evaluate the efficacy and safety of the drug candidate for the prevention of chemotherapy-induced diarrhea. The study is planned to enroll 138 patients with colorectal cancer, who will be randomized to receive subcutaneous treatment with elsiglutide or placebo in parallel with 5- fluorouracil (5-FU)-based chemotherapy. In connection with the start of the Phase IIa study, Zealand Pharma received EUR 1 million from Helsinn. Management s review Pipeline overview Zealand Pharma has seven peptide drug candidates in clinical or near clinical development, designed to offer better treatment for patients with diabetes, metabolic, gastrointestinal and cardiovascular diseases. Five of the seven programs are covered and fully financed under partnership agreements with pharmaceutical companies. Drug candidates for diabetes and related metabolic diseases Three Zealand Pharma discovered diabetes/metabolic peptide drug candidates are in development lixisenatide (Lyxumia ), lixisenatide/lantus combination pen and ZP2929. Further, the company is working on several earlier stage discovery and preclinical drug projects targeting better treatment in this field. Through its partnerships with two of the world s leading diabetes companies, Sanofi and Boehringer Ingelheim, Zealand Pharma holds a unique position to further grow its presence as a provider of novel treatments for the benefit of patients with diabetes and related metabolic diseases. Lixisenatide (Lyxumia ) For Type 2 diabetes (partnership with Sanofi) Lixisenatide (Lyxumia ) is a GLP-1 receptor agonist for once-daily administration, discovered by Zealand Pharma and developed by Sanofi for the treatment of Type 2 diabetes. Lyxumia is the intended trademark for lixisenatide. Lixisenatide is not currently approved or licensed anywhere in the world. Lixisenatide has been assessed in an extensive global Phase III program, GetGoal, which has involved more than 4,500 Type 2 diabetes patients. Throughout the GetGoal Phase III program, lixisenatide has delivered Zealand Pharma A/S Page 3 of 11
4 positive results, supporting the efficacy and safety of the drug as a monotherapy, in combination with oral anti-diabetes drugs and in combination with basal insulin. In November 2011, a Marketing Authorisation Application (MAA) by Sanofi for lixisenatide (Lyxumia ) was filed with the European Medicines Agency (EMA). Submission for regulatory approval of lixisenatide in the United States is planned for Q As requested by the American authorities, FDA, the US submission will include 12 month cardiovascular safety data from some of the studies in the GetGoal program and expected interim safety data also from a large ongoing CV outcome study, ELIXA. ELIXA evaluates cardiovascular safety of lixisenatide in up to 6,000 Type 2 diabetes patients with a history of a cardiac event and full study completion is expected in Lixisenatide/Lantus combination pen For Type 2 diabetes (partnership with Sanofi) Sanofi is also developing lixisenatide in a combination pen with Lantus, their world-leading insulin product. The combination pen planned to allow for flexible dosing of Lantus with a fixed dose of lixisenatide and the program is on track for start of Phase III studies in early ZP2929 For Type 2 diabetes and obesity (partnership with Boehringer Ingelheim) ZP2929 is a dual-acting glucagon/glp-1 agonist, designed by Zealand Pharma to be a potent synthetic agonist with effect on both the glucagon and the GLP-1 receptors. Zealand Pharma and Boehringer Ingelheim are advancing preparations of ZP2929 towards first human dosing. The first clinical study will be conducted by Zealand Pharma, while Boehringer Ingelheim will be responsible for the clinical development thereafter and finances all clinical development including Phase I. Drug candidates for gastrointestinal diseases Two Zealand Pharma discovered GLP-2 peptide drug candidates are in development targeting improved treatment options for patients suffering from certain gastrointestinal diseases. Elsiglutide For the prevention of chemotherapy-induced diarrhea (partnership with Helsinn Healthcare) Elsiglutide is a potent and selective GLP-2 agonist licensed to Helsinn Healthcare. Helsinn is evaluating elsiglutide in a Phase IIa study for the prevention of diarrhea in colorectal cancer patients treated with chemotherapy of the 5-FU type. In parallel, Helsinn is completing a Phase Ib study with elsiglutide, with results so far showing that the drug candidate is safe and well tolerated at doses above the expected therapeutic dose in colorectal cancer patients. ZP1848 For Inflammatory Bowel Diseases ZP1848 is another novel GLP-2 peptide agonist evaluated by Zealand Pharma in Phase Ia and Ib studies with positive results and now under evaluation for the next development step. Drug candidates for cardiovascular drug candidates Danegaptide For cardiovascular disorders Danegaptide is a small and potent, first-in-class peptide drug candidate, acting as a second-generation gap junction modifier. Zealand Pharma owns the global rights to danegaptide and is currently evaluating the drug candidate towards next development step. Zealand Pharma A/S Page 4 of 11
5 ZP1480 For post-surgical kidney injury (partnership with Action Pharma) ZP1480 is a first-in-class melanocortin peptide agonist, discovered by Action Pharma and modified with Zealand Pharma s SIP technology. All rights to ZP1480 (AP214) are owned by Action Pharma. Action Pharma has evaluated ZP1480 in a Phase IIb study with positive results for the treatment of postsurgical kidney injury in patients with cardiac disease. Organisation and Management The average number of employees in the organisation has increased to 101 in the first three months of 2012 from 85 in the same period last year. The increase is a consequence of a higher activity level in the research and development organisation mainly related to the research collaboration with Boehringer Ingelheim. Zealand Pharma A/S Page 5 of 11
6 Key Figures for the group The Board of Directors and Executive Management have approved this interim report containing condensed financial information for the first three months of 2012 ending 31 March The report is prepared in accordance with IAS 34 as endorsed by the EU and the additional Danish disclosure requirements for listed companies. The accounting principles are unchanged in the three months of 2012 and reference is made to the Annual Report 2011 for a more detailed description of the accounting policies. DKK thousand INCOME STATEMENT AND COMPREHENSIVE INCOME Q1 Q1 Full year Revenue 120, ,284 Royalty expenses -15, Gross profit 105, ,172 Research and development expenses -42,188-39, ,938 Administrative expenses -6,053-5,855-34,905 Other operating income 8,860 1,883 28,435 Operating result 65,632-43,314 8,764 Net financial items 54-1,590 4,613 Net result for the period 65,686-44,904 13,377 Comprehensive income for the period 65,686-44,904 13,377 Earnings per share - basic (DKK) Earnings per share - diluted (DKK) March 31 March 31 December BALANCE SHEET Cash and cash equivalents 326, , ,342 Securities 199, , ,358 Total assets 553, , ,481 Share capital ('000 shares) 23,193 22,871 23,193 Shareholder's equity 512, , ,397 Equity / assets ratio March 31 March 31 December CASH FLOW Depreciation 1, ,130 Change in working capital 27, ,943 Investments in fixed assets -2,683-2,786-11,475 Free cash flow 98,217-42,816-13, March 31 March 31 December OTHER Share price DKK Equity per share DKK Average number of employees Compounds in clinical development (end period) Zealand Pharma A/S Page 6 of 11
7 Financial Review (Comparative figures for the same period last year are shown in brackets) Income statement The net result for the first three months of 2012 was a profit of DKK 65.7 million (-44.9). The increased profit is mainly a result of milestone payments received from the license agreements with Sanofi and Helsinn Healthcare. Revenue Revenue for the first three months of 2012 increased to DKK million (0.0) and consisted of milestone payments from the agreements with Sanofi and Helsin Healthcare. Royalty expenses Royalty expenses for the period was DKK 15.3 million (0.0) and were related to the milestone payments from Sanofi and Helsinn Healthcare. Research and development expenses Research and development expenses amounted to DKK 42.2 million (39.3) which were in line with expectations. R&D expenses related to ZP2929 and the research collaboration with Boehringer Ingelheim have been refunded and recorded as other operating income, see below. Administrative expenses Administrative expenses for the period were in line with expectations and previous year and amounted to DKK 6.1 million (5.9). Other operating income Other operating income for the first three months of 2012 amounted to DKK 8.9 million (1.9) mainly associated with income under the agreement with Boehringer Ingelheim, relating to funding of development costs for ZP2929 and costs related to the research collaboration. Operating result Operating result for the period was a profit of DKK 65.6 million (-43.3). Net financial items Net financial items for the first three months of 2012 amounted to DKK 0.1 million (-1.6). Net financial items consist of interest income, banking fees and regulations based on changes in exchange rates. Result from ordinary activities before tax Result from ordinary activities before tax in the period came to a profit of DKK 65.7 million (-44.9). Tax on ordinary activities No tax on the result from ordinary activities has been recorded since Zealand Pharma offsets any tax through tax losses carry forward from previous years. No deferred tax asset has been recognized in the balance sheet due to uncertainty as to whether tax losses can be utilized. Net result Net result for the first three months of 2012 amounted to a profit of DKK 65.7 million (-44.9). Zealand Pharma A/S Page 7 of 11
8 Equity Equity stood at DKK million (369.3) at the end of the period, corresponding to an equity ratio of 93 % (90). The increase in equity is a result of profits made during the last 12 months as well as the exercise of warrants in December of Capital expenditure Investments in new laboratory equipment for the period amounted to DKK 2.7 million (2.8). Cash flow As of 31 March 2012, Zealand Pharma had cash and cash equivalents including securities of DKK million (390.2). The cash flow from operating activities amounted to DKK million (-40.0), and cash flow used for investing activities to DKK million (102.8) of which DKK 50.0 million (100.0) has been invested in securities. The total cash flow for the first three months of 2012 amounted to DKK 48.2 million (-142.8). Financial outlook for 2012 Revenue from milestone payments already received in 2012 from Sanofi and Helsinn Healthcare amounts to DKK 120 million with related royalty expenses of DKK 15 million. The timing of other potential milestone based payments from partners is largely outside the control of Zealand Pharma, and therefore no further revenue guidance is provided for the full year at this point. Total operating expenses for 2012 are expected in the range of DKK million. Hereof, approximately DKK 30 million is expected to be funded via operating income under partner agreements, corresponding to expected net operating expenses of DKK million. Risk factors This interim report contains forward-looking statements, including forecasts of future expenses as well as expected business related events. Such statements are subject to risks and uncertainties as various factors, some of which are beyond the control of Zealand Pharma, may cause actual results and performance to differ materially from the forecasts made in this interim report. Without being exhaustive, such factors include e.g. general economic and business conditions, including legal issues, scientific and clinical results, fluctuations in currencies etc. A more extensive description of risk factors can be found in the 2011 Annual Report under the section Risk management and internal control. Zealand Pharma A/S Page 8 of 11
9 Management s Statements on the Interim Report The Board of Directors and the Executive Management have today considered and adopted the interim report of Zealand Pharma A/S for the period 1 January 31 March The interim report has not been audited or reviewed by the company s independent auditor. The report is prepared in accordance with IAS 34 as endorsed by the EU and the additional Danish disclosure requirements for listed companies. The accounting principles are unchanged in the first three months of 2012 and reference is made to the Annual Report 2011 for a more detailed description of the accounting policies. In our opinion, the interim report gives a true and fair view of the Group s assets, equity and liabilities and financial position at 31 March 2012 and of the results of the Group s operations and the Group s cash flows for the period 1 January 31 March Moreover, in our opinion, the Management s Review and Financial Review gives a true and fair view of developments in the Group s operations and financial position and describes the most significant risks and uncertainty factors that may affect the Group. Copenhagen, 25 April 2012 Executive Management David H. Solomon Mats Blom Arvind M. Hundal President and CEO SVP and CFO SVP and CBO Christian Grøndahl EVP and CSO John Hyttel SVP and COO Board of Directors Daan J. Ellens Chairman Jørgen Lindegaard Vice chairman Alain Munoz Peter Benson Florian Reinaud Jutta af Rosenborg Christian Thorkildsen Helle Størum Zealand Pharma A/S Page 9 of 11
10 CONSOLIDATED INCOME STATEMENT (DKK'000) Q1 Q1 Full year Revenue 120, ,284 Royalty expenses -15, Gross profit 105, ,172 Research and development expenses -42,188-39, ,938 Administrative expenses -6,053-5,855-34,905 Other operating income 8,860 1,883 28,435 Operating result 65,632-43,314 8,764 Financial income 965 2,377 6,564 Financial expenses ,967-1,951 Result from ordinary activities before tax 65,686-44,904 13,377 Tax on ordinary activities Net result for the period 65,686-44,904 13,377 Comprehensive income for the period 65,686-44,904 13,377 Earnings per share - basic (DKK) Earnings per share - diluted (DKK) March 31 March 31 December CONSOLIDATED BALANCE SHEET (DKK '000) ASSETS Plant and machinery 15,470 9,902 14,856 Other fixtures and fittings, tools and equipment Leasehold improvements 2,112 2,175 1,968 Fixed assets under construction Deposits 2,508 2,440 2,493 Non current assets total 21,337 14,793 20,367 Trade receivables ,894 Prepaid expenses 3,941 2,906 1,080 Other receivables 2, ,440 Securities 199, , ,358 Cash and cash equivalents 326, , ,342 Current assets total 532, , ,114 Total assets 553, , ,481 LIABILITIES AND EQUITY Share capital 23,193 22,871 23,193 Retained earnings 489, , ,204 Equity total 512, , ,397 Trade payables 10,498 8,160 8,592 Prepayment from customers 2, ,284 Other liabilities 27,771 31,337 10,208 Current liabilities 40,766 39,497 28,084 Total liabilities 40,766 39,497 28,084 Total equity and liability 553, , ,481 Zealand Pharma A/S Page 10 of 11
11 CONSOLIDATED STATEMENT OF CASH FLOWS (DKK '000) Q1 Q1 Full year Profit / loss for the period 65,686-44,904 13,377 Adjustments 6,679 9,669 12,372 Change in working capital 27, ,943 Cash flow from operating activities before financing items 100,241-36,147-5,194 Financial income 1, ,339 Financial expenses paid ,967-1,951 Cash flow from operating activities 100,900-40,030-1,806 Change in deposit Investments in fixed assets -2,683-2,786-11,475 Purchase of securities -49, ,000-99,685 Cash flow from investing activities -52, , ,213 Capital increase 0 0 8,482 Repurchase of own shares Cash flow from financing activities 0 0 8,056 Decrease / increase in cash and cash equivalents 48, , ,963 Cash and cash equivalents at beginning of period 278, , ,305 Cash and cash equivalents at end of period 326, , ,342 Share Retained CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (DKK '000) capital earnings Total Equity at 1 January , , ,108 Warrants compensation expenses 0 7,118 7,118 Comprehensive income for the period 0-44,904-44,904 Equity at 31 March , , ,322 Equity at 1 January , , ,397 Warrants compensation expenses 0 5,512 5,512 Comprehensive income for the period 0 65,686 65,686 Equity at 31 March , , ,595 Changes in share capital Share capital at 31 December ,682 Capital increase at 23 November ,337 Capital increase at 9 December Capital increase at 12 December Share capital at 31 December ,193 Share capital at 31 March ,193 Zealand Pharma A/S Page 11 of 11
Financial results in line with expectations and important progress of the pipeline
Company Announcement - No. 37 / 2015 Zealand Interim report for H1 2015 (un-audited) Financial results in line with expectations and important progress of the pipeline Growing lixisenatide (Lyxumia ) royalty
More informationZealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress
Company Announcement No. 48 / 2015 Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress Lyxumia royalties and milestone
More informationZealand announces full year results in line with guidance and release of its Annual Report for 2015
Company announcement No. 5 / 2016 Zealand announces full year results in line with guidance and release of its Annual Report for 2015 2015 was a transitional year for Zealand with considerable business
More informationFinancial statements for the year ending 31 December 2010
Company Announcement No. 02/2011 10 February 2011 For the full year 2010 Zealand Pharma generated revenue of DKK 87.4 (EUR 11.7) million, compared to DKK 25.3 (EUR 3.4) million in 2009, and recorded a
More informationGROWING THE BUSINESS WITH 2015 AS A CATALYST YEAR
ZEALAND GROWING THE BUSINESS WITH 2015 AS A CATALYST YEAR US Roadshow June 2015 ZEALAND PHARMA DISCLAIMER This presentation does not constitute or form part of and should not be construed as, an offer
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationAccelerating our business from peptides to patients
Accelerating our business from peptides to patients Jeffries Global Healthcare Conference London, 19 November 2015 Zealand Pharma A/S Disclaimer This presentation does not constitute or form part of and
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationReport for the fourth quarter of 2016 and subsequent events (Un-audited)
SERODUS ASA Report for the fourth quarter of 2016 and subsequent events (Un-audited) Oslo, 27 February 2017 04-17 2016 Q4 report ABOUT SERODUS Serodus has been delisted from Oslo Axess and is now a private
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationREATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationMaking a difference in patients lives
Making a difference in patients lives building a portfolio of metabolic and gastrointestinal medicines June 2017 1 Forward-looking statements This presentation contains information pertaining to Zealand
More informationSunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights November 10, 2014 7:00 AM ET Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationOncolytics Biotech Inc. Announces Third Quarter 2010 Results
November 10, 2010 Oncolytics Biotech Announces Third Quarter 2010 Results CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationEiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 Eiger
More informationNewron announces 2018 financial results and provides outlook for 2019
Newron announces 2018 financial results and provides outlook for 2019 Milan, Italy, March 5, 2019 Newron Pharmaceuticals S.p.A. ( Newron ), a biopharmaceutical company focused on the development of novel
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationSmall-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK
Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:
More informationPhotoCure ASA Presentation First quarter 2005 May 3, 2005
PhotoCure ASA Presentation First quarter 2005 May 3, 2005 Obtaining milestones and building value Hexvix Approval in 27 EU/EEA countries, working on national approvals Ongoing phase III study for extended
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationALK-Abelló A/S. Click View,Header and Footer to change this text to filename and department name
ALK-Abelló A/S June 25, 2008 Click View,Header and Footer to change this text to filename and department name 1 Changing the way we treat allergy Piper Jaffray 19th Annual Health Care Conference, New York
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationValneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationQUARTERLY REPORT 2. September 2017 February Diamyd Medical AB (publ), Fiscal year 2017/2018
QUARTERLY REPORT 2 September 2017 February 2018 Diamyd Medical AB (publ), Fiscal year 2017/2018 The diabetes vaccine Diamyd continues to show promising results from the DIAGNODE-1 trial where the diabetes
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationThe Dual Hormonal Artificial Pancreas in Diabetes Management. Medical Innovation Day Challenge
The Dual Hormonal Artificial Pancreas in Diabetes Management Medical Innovation Day Challenge 1 Background for the challenge A paradigm shift in treating diabetes Zealand Pharma is a Danish biotech company
More informationThromboGenics Business Update H1 2018
Press release 6 September 2018 Regulated Information ThromboGenics Business Update H1 2018 Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationBayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration International
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationSANIONA COMPANY PRESENTATION
SANIONA COMPANY PRESENTATION MARCH, 2016 March 2016 1 THE SANIONA WAY Low burn rate without compromising on high ambitions Top class science World-class research team focused on ion channels CNS, pain,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationReport for the third quarter of 2015 (un-audited)
SERODUS ASA Report for the third quarter of 2015 (un-audited) Oslo, 27 October 2015 Serodus Q3-2015 Report ABOUT SERODUS Serodus ASA is a Norwegian drug development company, focusing on new therapeutic
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationHIGH CLINICAL ACCEPTANCE OF METVIX PDT
HIGH CLINICAL ACCEPTANCE OF METVIX PDT PhotoCure ASA Second Quarter Report 2002 Highlights: Marketing of Metvix PDT in Europe Progressing as Planned Positive Phase III Clinical Results in the Treatment
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationQUARTERLY REPORT 3. September 2017 May Diamyd Medical AB (publ), Fiscal year 2017/2018
QUARTERLY REPORT 3 September 2017 May 2018 Diamyd Medical AB (publ), Fiscal year 2017/2018 Two drugs in clinical development Diamyd to preserve the endogenous insulin production in autoimmune diabetes
More informationVICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06
VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationTherapeutic products for respiratory and autoimmune diseases. Annual General Meeting
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationAmylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationPresentation First quarter 2006
Immunity for Life TM Presentation First quarter 2006 CEO Gunnar Rørstad CFO Finn Samuelsen 10 May 2006 Highlights - operations Inclusion of patients almost completed in the the phase II clinical trial
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More information